cluding cAMP-dependent protein kinase/protein kinase A (PKA), 3, 4 protein kinase B (Akt/PKB1), 5 P70-S6 kinase (S6 K), 6 and extracellular signal-regulated kinase (ERK), 7 all of which play important roles in prostate cancer progression. In post-sprint muscle, high glycolytic rate, marked lactate accumulation, and hypoxia were associated with increased p-Ser-486/491 AMPKα1/α2 8 ; a similar environment can be found within the prostate tumor and is associated with metastasis and poor prognosis. 9 Chemical agents that activate AMPKα lead to death of prostate cancer cells. 10, 11 Elevated fatty acid and cholesterol biomarkers were identified in the serum of prostate cancer patients who progressed to castration-resistant prostate cancer (CRPC) within 1 year of endocrine therapy, compared to those who did not progress. 12 Metabolomic analysis identified significantly elevated levels of cholesterol, fatty acids, and amino acids within prostate cancer bone metastases, 13 
| Statistical analysis
The association between two categorical variables was estimated using Patients in the non-metastatic group were significantly more likely to self-report a first-or second-generation relative with cancer (this data is missing in 10% of non-metastatic and 26.7% of metastatic patient records) (Table 2) . Surprisingly, this significance dematerialized when solely analyzing self-reported first-or second-generation relatives diagnosed with prostate, breast, or ovarian cancers. Comorbidities significantly associated with non-metastatic prostate cancer included prostatic intraepithelial neoplasia (PIN) and colon polyps; whereas Type 2 diabetes and hypertension were more significantly associated with metastatic disease.
| Pathological characteristics of prostate tumors
The most common sites of prostate cancer metastasis were bone (77.8%), bladder, levator muscles, and/or pelvic wall). All non-metastatic patients were Gleason 6 or 7 on biopsy; whereas metastatic patients ranged from Extraprostatic extension, perineural invasion, and positive margins were significantly more frequent in metastatic than in non-metastatic RP specimens; seminal vesicle invasion was also more frequent in metastatic RP specimens, although not significantly so. staining was significantly more intense (2.5×) in castrationresistant specimens than in hormone-dependent specimens (Table 5 ). p-Ser-486/491 AMPKα/α staining was significantly associated with increasing biopsy Gleason score, whereas p-Ser-872 HMG-CoAR was significantly inversely correlated with increasing biopsy Gleason score in primary prostate cancer specimens (Table 6 ). p-Ser-79 ACC also demonstrated a decreasing trend with increasing Gleason grade, but did not reach statistical significance. In non-metastatic primary prostate cancer specimens, AMPKα protein expression and phosphorylation are found in both the cytoplasm and nucleus; whereas, staining becomes significantly more cytoplasmic localized and nuclear staining lost in metastasis specimens (Table 7 and Figure 2 ). Colon polyps as a notable comorbidity was not a pre-analysis hypothesis, and instead was observed during data analysis. *P < 0.05. **P < 0.01, by chi-square test.
CRPC and metastatic prostate cancer could use more options in their treatment toolbox; identification of drugs which reduce the inhibitory Ser-486/491 phosphorylation by suppression of upstream kinases and/or increase AMPKα activity may be effective treatment for metastatic or CRPC.
Interestingly, we observed that AMPKα protein expression and phosphorylation pattern became significantly cytoplasmic in metastatic group primary and secondary site specimens than in non-metastatic subject primary prostate tumor specimens. Our results suggest that with prostate cancer progression to metastasis, AMPKα loses nuclear localization; one consequence of this is loss of control over the glucose-sensitive G1/S cell cycle checkpoint regulated by AMPKα. When activated, nuclear AMPKα phosphorylates p53 on Ser-15 and initiates AMPK-dependent cell cycle arrest; disruption of this checkpoint permits unchecked proliferation, even with limiting nutrients. 15 In our previous work, we observed that metastatic CRPC cell lines arrested in G1 phase and underwent death by necroptosis following re-activation of AMPKα with combination statin and metformin, 16 akin to the observation of Jones et al 15 that activation of AMPK with AICAR increased PSA, prostate-specific antigen; normal PSA <4.0 ng/mL. RP, radical prostatectomy; all 30 non-metastatic cases underwent RP, whereas only 12 metastatic cases underwent RP. *P < 0.01. **P <0.0001. 
